None
SEDAR Interim Financial Statements
SVA · Price
[
{
"companyName": "SERNOVA BIOTHERAPEUTICS INC.",
"reportingPeriodEnd": "2026-01-31",
"reportStatus": "Unaudited",
"auditorName": null,
"auditorKeyMatters": [],
"balanceSheet": {
"cash": 576221,
"amountsReceivable": 125587,
"prepaidExpensesAndOtherAssets": 73860,
"totalCurrentAssets": 775668,
"deposits": 223860,
"equipmentNet": 13293,
"totalNonCurrentAssets": 237153,
"totalAssets": 1012821,
"accountsPayableAndAccruedLiabilities": 9065692,
"accountsPayableToBeSettledInEquity": 12605835,
"loanPayable": 3864073,
"totalCurrentLiabilities": 25535600,
"convertibleDebentures": 1079368,
"totalNonCurrentLiabilities": 1079368,
"totalLiabilities": 26614968,
"commonShares": 119978119,
"warrants": 660997,
"contributedSurplus": 22195747,
"deficit": -168437010,
"totalShareholdersDeficit": -25602147,
"totalLiabilitiesAndShareholdersDeficit": 1012821,
"cashPerShare": 0.0017,
"workingCapitalPerShare": -0.0736
},
"incomeStatement": {
"researchAndDevelopment": 434149,
"generalAndAdministrative": 1680871,
"totalOperatingExpenses": 2115020,
"interestIncome": 0,
"financeCosts": 477117,
"foreignExchangeGainLoss": -185735,
"netOtherExpense": 291382,
"netLossBeforeIncomeTaxes": 2406402,
"currentIncomeTaxRecoveryExpense": -72000,
"netLossAndComprehensiveLoss": 2334402,
"basicAndDilutedNetLossPerCommonShare": 0.01,
"weightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": 336396195
},
"cashFlowStatement": {
"netLoss": -2334402,
"amortizationAndDepreciation": 4431,
"shareBasedCompensation": 403730,
"researchCollaborationAdvancesRecognizedAsCostRecoveries": 0,
"interestOnLeaseLiabilities": 0,
"accretionAndAccruedInterestExpense": 217025,
"changesInAmountsReceivable": -2954,
"changesInPrepaidExpensesAndOtherAssets": 61153,
"changesInAccountsPayableAndAccruedLiabilities": 604129,
"netCashUsedInOperatingActivities": -1046888,
"netCashProvidedByInvestingActivities": 0,
"proceedsFromPrivatePlacementOfSharesNet": 1358105,
"researchCollaborationAdvances": 0,
"leaseLiabilitiesPayments": 0,
"netCashProvidedByFinancingActivities": 1358105,
"netIncreaseDecreaseInCash": 311217,
"cashBeginningOfPeriod": 265004,
"cashEndOfPeriod": 576221,
"incomeTaxesPaid": 4778,
"interestReceived": 0
},
"investmentsAndOtherAssets": [],
"shareStructure": {
"authorizedShares": "unlimited",
"issuedShares": 342080895,
"classesOfShares": ["common", "preferred"],
"warrants": [
{
"number": 9000000,
"exercisePrice": 0.20,
"expiryDate": "2028-04-16"
},
{
"number": 5000000,
"exercisePrice": 0.20,
"expiryDate": "2028-03-04"
},
{
"number": 666667,
"exercisePrice": 0.25,
"expiryDate": "2028-07-07"
},
{
"number": 666667,
"exercisePrice": 0.25,
"expiryDate": "2028-07-21"
},
{
"number": 666667,
"exercisePrice": 0.25,
"expiryDate": "2028-09-02"
},
{
"number": 3843750,
"exercisePrice": 0.40,
"expiryDate": null
},
{
"number": 5382334,
"exercisePrice": 0.25,
"expiryDate": null
},
{
"number": 290880,
"exercisePrice": 0.30,
"expiryDate": null
}
],
"options": [
{
"number": 8398612,
"exercisePrice": 0.25,
"expiryDate": null
},
{
"number": 23192473,
"exercisePrice": 0.26,
"expiryDate": null
},
{
"number": 903750,
"exercisePrice": 1.18,
"expiryDate": null
}
],
"rightsConvertibleInstruments": "Convertible debentures: $1,000,000 at 15% (conversion $0.20), $100,000 at 12% (conversion $0.15), $100,000 at 12% (conversion $0.15), $100,000 at 10% (conversion $0.15). Loan payable: $4,000,000 at 14.25-15.25% due April 16, 2026."
},
"managementCompensation": {
"currency": "CAD",
"periods": {
"2026-01-31": {
"personnelCosts": 754114,
"directorFees": 81250,
"shareBasedCompensation": 311719,
"total": 1147083
},
"2025-01-31": {
"personnelCosts": 777765,
"directorFees": 54098,
"shareBasedCompensation": 687831,
"total": 1519694
}
},
"namedIndividuals": [],
"otherRelatedPartyTransactions": [
{
"counterparty": "Director",
"description": "Convertible debentures outstanding",
"amount": 1079368,
"period": "2026-01-31"
},
{
"counterparty": "Director",
"description": "Unsecured debt and interest payable",
"amount": 92874,
"period": "2026-01-31"
},
{
"counterparty": "Executive Officers",
"description": "Salaries and fees payable at 12% interest, including portion to be settled in equity",
"amount": 1379448,
"period": "2026-01-31"
},
{
"counterparty": "Board Member",
"description": "Warrants issued for loan guarantee",
"amount": 340200,
"period": "2025-04-16"
}
]
},
"subsequentEvents": [
{
"eventDate": "2026-03",
"description": "Amended terms of 19,997,050 warrants (originally expiring March 3, 2026) to extend expiry by one year to March 3, 2027.",
"impactValue": null
},
{
"eventDate": "2026-03",
"description": "Amended terms of 5,571,250 warrants (exercise price $0.40) to reduce exercise price to $0.25 and add acceleration provision if 5-day VWAP exceeds $0.50.",
"impactValue": null
},
{
"eventDate": "2026-03",
"description": "Completed non-brokered private placement of 5,645,439 units at $0.15 for gross proceeds of $846,816.",
"impactValue": 846816
},
{
"eventDate": "2026-03",
"description": "Issued $1,500,000 convertible debenture to a Director (conversion price $0.15, 10% interest) with 10,000,000 warrants at $0.25, subject to TSX approval.",
"impactValue": 1500000
},
{
"eventDate": "2026-03",
"description": "Entered subscription agreement with a Director for $4.0 million equity financing (26,666,667 units at $0.15) to retire loan payable, subject to shareholder approval.",
"impactValue": 4000000
}
]
}
]
More from Sernova Biotherapeutics Inc
Jun 17, 2026 · 07:00